Germline RAD51B Variants Confer Susceptibility to Breast and Ovarian Cancers Deficient in Homologous Recombination

Investigators demonstrated that tumors harboring biallelic RAD51B alteration were deficient in homologous recombination DNA repair deficiency, as evidenced by analysis of sequencing data and in vitro functional assays.
[npj Breast Cancer]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

RNA Binding Protein RBMS3 Is a Common EMT Effector That Modulates Triple-Negative Breast Cancer Progression via Stabilizing PRRX1 mRNA

Scientists identified RNA Binding Motif Single Stranded Interacting Protein 3 (RBMS3) as a novel and common effector of epithelial-to-mesenchymal transition (EMT), which could be a promising therapeutic target for triple-negative breast cancer treatment.
[Oncogene]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization

Gilead Sciences, Inc. announced that Health Canada has approved Trodelvy® for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior therapies, at least one of them for metastatic disease.
[Gilead Sciences, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Telix Pharmaceuticals Limited announced that a first patient has been dosed in a Phase II study of TLX250-CDx in patients with TNBC.
[Telix Pharmaceuticals]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Targeting Neurons in the Tumor Microenvironment with Bupivacaine Nanoparticles Reduces Breast Cancer Progression and Metastases

The authors designed PEGylated lipid nanoparticles loaded with a non-opioid analgesic, bupivacaine, to target neurons within breast cancer tumors and suppress nerve-to-cancer cross-talk.
[Science Advances]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

CD47-Targeted Cancer Immunogene Therapy: Secreted SIRPα-FC Fusion Protein Eradicates Tumors by Macrophage and NK Cell Activation

Researchers developed a plasmid-vector encoding for the secreted fusion protein sCV1-hIgG1, comprising of highly efficient CD47-blocking moiety CV1 and Fc domain of human IgG1 with maximized immune activation.
[Molecular Therapy-Oncolytics]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Recurrence Biomarkers of Triple Negative Breast Cancer Treated with Neoadjuvant Chemotherapy and Anti-EGFR Antibodies

To find metastatic recurrence biomarkers of TNBC treated by neoadjuvant chemotherapy and anti-EGFR antibodies, investigators evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E.
[npj Breast Cancer]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Therapeutic Inhibition of USP9x-Mediated Notch Signaling in Triple-Negative Breast Cancer

Using a murine TNBC model, scientists showed that USP9x knockdown abrogated Notch activation, reducing the production of the proinflammatory cytokines, C-C motif chemokine ligand 2 and interleukin-1 beta.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

T-Cure Bioscience Announces US FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T against Multiple Solid Tumors

T–Cure Bioscience, Inc. announced that the US FDA has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a T cell receptor (TCR)–based product candidate for the treatment of tumors expressing Kita–Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, lung, breast cancers and other KK–LC–1 positive epithelial cancers.
[T–Cure Bioscience, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Synergistic PIM Kinase and Proteasome Inhibition as a Therapeutic Strategy for MYC-Overexpressing Triple-Negative Breast Cancer

The PIM family of kinases has emerged as a factor that is both overexpressed in TNBC and associated with poor outcomes. The authors’ screening effort identified PIM and the 20S proteasome inhibition as the most synergistic combination.
[Cell Chemical Biology]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Transcriptional Landscape Associated with Triple Negative Breast Cancer (TNBC) Resistance to Neoadjuvant Chemotherapy Revealed by Single Cell RNA-Seq

Scientists identified the transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy at the single cell level by analyzing publicly-available transcriptome data from more than 5,000 single cells derived from four extinction and four persistence patients, revealing remarkable tumor heterogeneity.
[Molecular Therapy-Oncolytics]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share
Share